Navigation Links
Cell Metabolism Publishes Novel TGR5-Mediated Mechanism for the Treatment of Diabetes and Obesity
Date:9/1/2009

he clinic in 2010."

About Intercept Pharmaceuticals

Intercept is a clinical stage biopharmaceutical company focused on discovering and developing small molecule drugs for the treatment of chronic fibrotic and metabolic diseases. The company's most advanced programs are focused on the development of modified bile acids that are selective for FXR, a nuclear receptor, and TGR5, a G protein-coupled receptor. Bile acid signaling through these receptors regulates key aspects of lipid, glucose and overall energy metabolism, while also serving to maintain the functional integrity of the liver, intestine and kidney, organs that are exposed to bile acid flux.

Intercept's lead compound, INT-747, is a modified human bile acid and first-in-class FXR agonist that is currently in Phase II testing. Clinical proof of concept was recently demonstrated in a Phase II, placebo-controlled trial of INT-747 in type 2 diabetics with fatty liver disease. Based on these results, the company plans to advance INT-747 in a Phase IIb trial in patients with nonalcoholic steatohepatitis (NASH) in 2010. INT-747 is completing two additional Phase II trials in patients with primary biliary cirrhosis, an autoimmune cholestatic liver disease and orphan indication. Results from the first of the two studies are expected in the fourth quarter of 2009.

INT-777 is a modified human bile acid and selective TGR5 agonist that is currently being assessed in IND-enabling studies.

For more information about Intercept, please go to www.interceptpharma.com; and for information about Intercept's lead investor, Genextra S.p.A., please go to www.genextra.it.


'/>"/>
SOURCE Intercept Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ChartTrends(R): Bone and Mineral Metabolism in Dialysis Reveals Latest Trends in the Treatment of Calcium, Phosphorus and PTH
2. Circulation Publishes MERLIN TIMI-36 Data Showing Safety and Anti-Arrhythmic Effects of Ranexa(R)
3. Thomson Scientific Publishes Who Is Making The Biggest Splash? - A Quarterly Review of Scientific Literature on Drugs and Therapies From April - June 2007
4. Consortium publishes Phase II map of human genetic variation
5. The Lancet Publishes Vasogens ACCLAIM Results
6. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
7. The Lancet Publishes Results From Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
8. Springer publishes anthology with the Nanoethics Group
9. The Scientific Business of Thomson Reuters Publishes Its 2008 Liquent Regulatory Affairs Trends Survey Results
10. Waters Publishes Rapid and Specific Method of Detection for Melamine in Infant Formula and Liquid Milk, in Support of Chinas Ministry of Science and Technology
11. Bionovo Publishes Discoveries in Predictable Tissue Selectivity for Selective Estrogen Receptor Modulators Platform
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Controlled Substance Compliance Services (CSCS), a project managed ... legal requirements around using controlled substances in pharmaceutical research, ... their international operations expand and become increasingly complex, large ... a result of the first phase of the CSCS ...
(Date:1/22/2015)... Jan. 22, 2015   Cypher Genomics, Inc., ... (NASDAQ: SQNM ), the leading molecular ... next generation noninvasive prenatal tests (NIPT). Through this ... called Mantis™, to advance analysis of clinically-relevant fetal ...
(Date:12/25/2014)... The report “Service Quality Management and Telco ... Type - Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” ... and forecasting of revenues. , Browse 152 market ... in-depth TOC on “Service Quality Management (SQM) and Telco ...
(Date:12/24/2014)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... hypothermic storage and cryopreservation freeze media and ... ("BioLife" or the "Company"), today announced that it will hold ... (the "Annual Meeting"). Because the expected date for ...
Breaking Biology Technology:Global Compliance Service for Controlled Substances to Expand to China 2Cypher Genomics and Sequenom Announce Development Agreement 2Cypher Genomics and Sequenom Announce Development Agreement 3Cypher Genomics and Sequenom Announce Development Agreement 4Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... PALO ALTO, Calif., Oct. 24 Vivo Ventures, a ... that,James Huang will join the firm as an Executive ... Mr. Huang will,work with Vivo,s portfolio companies while enhancing ... James coming on board and what he will be ...
... 24 Cell Therapeutics,Inc. (CTI) (Nasdaq and ... 19th annual AACR-NCI-EORTC Symposium show its bis-platinate ... to currently,marketed platinum agents carboplatin, cisplatin and ... in late 2008. "Bis-platinates represent a ...
... is available in German . , Hydrogen fuel ... have so far suffered from being insufficiently competitive. At the ... Strasser has now developed a new class of electrocatalyst that ... active phase of the catalyst consists of nanoparticles with a ...
Cached Biology Technology:Vivo Ventures Expands Team with the Addition of James Huang as an Executive in Residence 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 2First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs 3Platinum-rich shell, platinum-poor core 2
(Date:1/22/2015)... Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), ... crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz ... production capacity to meet customer demand. ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by ...
(Date:1/22/2015)... 2015  BellBrook Labs, a leader in high throughput ... of a TR-FRET (time resolved Forster resonance energy ... a high throughput screening assay for glycosyltransferases and ... for sensitive detection of hundreds of human and ...
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2BellBrook Labs Launches a High Throughput Screening Assay for Glycosyltransferases with TR-FRET Readout 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... turfgrass has become increasingly restricted due to environmental ... and industrial consumption; and contamination of potable water ... need to identify promising water conservation strategies and ... In their ongoing search for ways to improve ...
... Washington, D.C. -- Disease statistics buried within patient ... and organized to depict geographic patterns, allowing the discovery ... Penn State geographer. "The use of interactive maps ... to greater insight into complex events like the spread ...
... The ELCC Press Program will feature new study ... (embargoed to time of their presentation at ELCC): ... Pemetrexed plus cisplatin with radiation in patients with locally ... therapeutic combination, Screening for lung cancer in organ transplant ...
Cached Biology News:Common PGR helps creeping bentgrass weather drought 2Visualization of geographic patterns may predict spread of disease 22nd European Lung Cancer Conference 22nd European Lung Cancer Conference 3
VEGF Receptor-2, phospho-specific (Tyr996)...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
Preadipocyte factor-1 [Pref-1, DLK-1], C-terminal...
IC50: 35 ng/ml · Limit of detection: 8 ng/ml...
Biology Products: